Share on StockTwits
 

Shares of Humana (NYSE:HUM) were the target of some unusual options trading on Monday. Stock investors acquired 21,060 call options on the company, Analyst Ratings News reports. This is an increase of 605% compared to the average daily volume of 2,987 call options.

A number of research firms have recently commented on HUM. Analysts at Zacks reiterated a “neutral” rating on shares of Humana in a research note on Thursday, February 6th. They now have a $100.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Humana from $115.00 to $111.00 in a research note on Thursday, February 6th. Finally, analysts at Barclays downgraded shares of Humana from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, January 8th. They now have a $109.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $101.12.

Humana (NYSE:HUM) opened at 100.23 on Tuesday. Humana has a one year low of $65.88 and a one year high of $105.80. The stock has a 50-day moving average of $97.92 and a 200-day moving average of $96.57. The company has a market cap of $15.438 billion and a price-to-earnings ratio of 12.55.

Humana (NYSE:HUM) last released its earnings data on Wednesday, February 5th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.95 by $1.14. The company had revenue of $10.20 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the company posted $1.19 earnings per share. The company’s quarterly revenue was up 6.6% on a year-over-year basis. On average, analysts predict that Humana will post $7.77 earnings per share for the current fiscal year.

Humana Inc (NYSE:HUM) is a health care company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.